Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Catalyst Pharmaceuticals, Inc. - Common Stock
(NQ:
CPRX
)
31.49
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
July 16, 2026
From
Angelini Pharma
Via
GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Growth and a High-Quality Technical Breakout Setup
↗
July 15, 2026
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth
↗
July 10, 2026
Via
Chartmill
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
↗
July 10, 2026
Catalyst Pharmaceuticals (NASDAQ:CPRX) stockholders approved the company’s proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company...
Via
MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Deep Value Play with Rare Disease Pipeline Strength
↗
July 02, 2026
Via
Chartmill
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
June 30, 2026
Data Demonstrate Vamorolone’s Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC
↗
June 24, 2026
Via
Chartmill
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
June 24, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shows Strong Growth and a Bullish Technical Setup
↗
May 26, 2026
Via
Chartmill
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal
↗
May 20, 2026
NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Scores 7/10 Fundamental Rating in Affordable Growth Screen
↗
May 11, 2026
Via
Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case
↗
April 18, 2026
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment
↗
March 21, 2026
Via
Chartmill
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case
↗
March 11, 2026
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup
↗
March 05, 2026
Via
Chartmill
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
May 11, 2026
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
May 09, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth
↗
May 09, 2026
This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S. market.
Via
The Motley Fool
Topics
Regulatory Compliance
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout
↗
February 26, 2026
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Beats Q4 Estimates, Issues Conservative 2026 Outlook
↗
February 25, 2026
Via
Chartmill
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
May 07, 2026
The Company will Report First Quarter 2026 Financial Results on May 11, 2026
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
May 07, 2026
From
Halper Sadeh LLC
Via
Business Wire
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
May 07, 2026
From
Angelini Pharma; Catalyst Pharmaceuticals
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
May 07, 2026
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
April 28, 2026
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup
↗
April 14, 2026
Catalyst Pharmaceuticals (CPRX) combines strong growth, high profitability, and a debt-free balance sheet with a positive technical trend, signaling a potential breakout opportunity.
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock
↗
April 10, 2026
Catalyst Pharmaceuticals (CPRX) exemplifies affordable growth with strong earnings, a debt-free balance sheet, and a valuation below industry averages.
Via
Chartmill
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
March 06, 2026
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
February 25, 2026
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
February 24, 2026
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.